KR100567125B1 - 칼콘 또는 이의 유도체를 함유하는 매트릭스메탈로프로테아제 활성 억제용 약학 조성물 - Google Patents
칼콘 또는 이의 유도체를 함유하는 매트릭스메탈로프로테아제 활성 억제용 약학 조성물 Download PDFInfo
- Publication number
- KR100567125B1 KR100567125B1 KR1020010067950A KR20010067950A KR100567125B1 KR 100567125 B1 KR100567125 B1 KR 100567125B1 KR 1020010067950 A KR1020010067950 A KR 1020010067950A KR 20010067950 A KR20010067950 A KR 20010067950A KR 100567125 B1 KR100567125 B1 KR 100567125B1
- Authority
- KR
- South Korea
- Prior art keywords
- chalcone
- mmp
- pharmaceutical composition
- activity
- disease
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Abstract
Description
저해제 | 억제활성(%) |
대조군 | 0 |
칼콘(Indofine chemical사) | 79.9 |
플로레틴(시그마사) | 87.2 |
4-메톡시 칼콘 | 92.7 |
2-히드록시 칼콘 | 90.4 |
4-히드록시 칼콘 | 95.9 |
4'-메톡시 칼콘 | 99.1 |
2',4'-디메톡시 칼콘 | 92.5 |
Claims (7)
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 4-메톡시 칼콘, 4'-메톡시 칼콘, 2-히드록시 칼콘, 4-히드록시 칼콘, 4'-히드록시 칼콘, 2', 4'-디메톡시 칼콘 및 칼콘으로 이루어진 그룹에서 선택된 화합물을 유효성분으로 함유하는 과다한 매트릭스 메탈로프로테아제 (MMP) 활성에 기인한 MMP-매개 골감소증, 알츠하이머 질환, 피부노화, 각막궤양, 이상 창상 유합, 단백뇨증, 신경계의 수초탈락 질환, 간경변, 신사구체 질환, 배태막의 미성숙 파열, 치근막 질환, 원추 각막, 쇼그렌 증후군, 각막이식 거부의 치료 및 예방을 위한 약학조성물
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020010067950A KR100567125B1 (ko) | 2001-11-01 | 2001-11-01 | 칼콘 또는 이의 유도체를 함유하는 매트릭스메탈로프로테아제 활성 억제용 약학 조성물 |
PCT/KR2002/002031 WO2003037315A1 (en) | 2001-11-01 | 2002-10-31 | Pharmaceutical composition containing chalcone or its derivatives for matrix metalloproteinase inhibitory activity |
EP02802394.3A EP1450777B1 (en) | 2001-11-01 | 2002-10-31 | Pharmaceutical composition containing chalcone or its derivatives for matrix metalloproteinase inhibitory activity |
ES02802394T ES2422891T3 (es) | 2001-11-01 | 2002-10-31 | Composición farmacéutica que contiene chalcona o derivados de la misma con actividad inhibidora de metaloproteinasas de matriz |
US10/838,853 US7572831B2 (en) | 2001-11-01 | 2004-05-03 | Composition containing chalcone |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020010067950A KR100567125B1 (ko) | 2001-11-01 | 2001-11-01 | 칼콘 또는 이의 유도체를 함유하는 매트릭스메탈로프로테아제 활성 억제용 약학 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030036993A KR20030036993A (ko) | 2003-05-12 |
KR100567125B1 true KR100567125B1 (ko) | 2006-03-31 |
Family
ID=19715615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020010067950A KR100567125B1 (ko) | 2001-11-01 | 2001-11-01 | 칼콘 또는 이의 유도체를 함유하는 매트릭스메탈로프로테아제 활성 억제용 약학 조성물 |
Country Status (5)
Country | Link |
---|---|
US (1) | US7572831B2 (ko) |
EP (1) | EP1450777B1 (ko) |
KR (1) | KR100567125B1 (ko) |
ES (1) | ES2422891T3 (ko) |
WO (1) | WO2003037315A1 (ko) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101220417B1 (ko) | 2010-11-04 | 2013-01-10 | 건국대학교 산학협력단 | 세포사멸 유도 활성을 갖는 칼콘 유도체 |
WO2013054998A1 (ko) * | 2011-10-13 | 2013-04-18 | 건국대학교 산학협력단 | 신규한 칼콘 유도체 및 이를 유효성분으로 하는 항암제 조성물 |
KR101389529B1 (ko) | 2012-02-03 | 2014-04-29 | 주식회사 스킨앤테크 | 가용화된 4-메톡시칼콘을 함유하는 피부 미백 조성물 및 이의 제조방법 |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100445640B1 (ko) * | 2001-12-05 | 2004-08-25 | 학교법인 원광학원 | 부테인의 간경화 및 간섬유증 치료제 조성물 |
WO2005002672A2 (en) * | 2003-07-01 | 2005-01-13 | President And Fellows Of Harvard College | Sirt1 modulators for manipulating cells/organism lifespan/stress response |
US20060025337A1 (en) * | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
AU2004312072B2 (en) * | 2003-12-29 | 2011-06-23 | President And Fellows Of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
WO2006138418A2 (en) * | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
US20090203773A1 (en) * | 2005-06-24 | 2009-08-13 | D Orazio Daniel | Compounds for the Treatment of Non-Autoimmune Type 2 Diabetes Mellitus and/or Syndrome X |
EP1951214A2 (en) * | 2005-09-19 | 2008-08-06 | Nitzozot Ltd. | Modulation of osteoclast differentiation |
TW200735866A (en) | 2005-11-18 | 2007-10-01 | Synta Pharmaceuticals Corp | Compounds for the treatment of proliferative disorders |
US7851654B2 (en) | 2006-04-03 | 2010-12-14 | Industry-Academic Cooperation Foundation Gyeongsang National University | Chalcone derivatives, pharmaceutically acceptable salt, method for preparation and uses thereof |
US20080103103A1 (en) * | 2006-10-30 | 2008-05-01 | Bahram Memarzadeh | Reagents and methods to treat ocular diseases and infection |
CN101147724A (zh) * | 2006-12-04 | 2008-03-26 | 好维股份有限公司 | 含甘草黄酮提取物的口腔药物或口腔卫生产品 |
KR100934706B1 (ko) | 2006-12-07 | 2009-12-31 | 재단법인서울대학교산학협력재단 | Tm4sf5의 기능을 저해하는 항암물질의 스크리닝 방법및 칼콘계 화합물을 함유하는 항암조성물 |
JP5196465B2 (ja) * | 2007-04-24 | 2013-05-15 | 公益財団法人東京都農林水産振興財団 | Mmp遺伝子発現促進剤、および、コラーゲン分解促進剤 |
AU2009319881C1 (en) * | 2008-11-26 | 2015-12-24 | Perio Sciences, Llc | Antioxidant compositions for soft oral tissue and methods of formulation and use thereof |
WO2011009826A2 (en) | 2009-07-21 | 2011-01-27 | ADAMED Sp.z o.o. | Novel chalcone derivatives with cytotoxic activity |
CN102647982B (zh) | 2009-11-26 | 2014-10-15 | 基恩菲特公司 | 使用1,3-二苯基丙-2-烯-1-酮衍生物治疗肝脏疾患 |
WO2011080276A1 (en) | 2009-12-29 | 2011-07-07 | Genfit | Pharmaceutical combinations comprising a dpp-4 inhibitor and a 1,3-diphenylprop-2-en-1-one derivative |
KR20120022504A (ko) | 2010-07-30 | 2012-03-12 | 서울대학교산학협력단 | 간 질환의 진단, 치료 및 예방용 조성물 |
DE102010033138A1 (de) * | 2010-08-03 | 2012-02-09 | Merck Patent Gmbh | Phenethyl-, Phenethylen-, Phenethin- und Indanonderivate |
US20120046353A1 (en) * | 2010-08-17 | 2012-02-23 | Choong Ang Vaccine Lab. | Cleistocalyx operculatus-derived compounds having inhibitory activities against avian and swine influenza viruses or novel influenza virus |
US10071945B2 (en) * | 2011-06-15 | 2018-09-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
TWI415600B (zh) * | 2011-08-10 | 2013-11-21 | Univ Kaohsiung Medical | 用於治療動脈粥狀硬化的組合物及其製備方法 |
KR101437052B1 (ko) * | 2011-08-30 | 2014-09-04 | 이화여자대학교 산학협력단 | 다이 또는 트라이신나모일벤젠 유도체를 염증 또는 신경질환의 예방 또는 치료용 약학적 조성물 |
CN102397269B (zh) * | 2011-09-20 | 2015-01-07 | 温州医学院 | 查尔酮类化合物在制备抗炎药物中的应用 |
KR101333735B1 (ko) * | 2011-11-01 | 2013-11-27 | 건국대학교 산학협력단 | 디페닐프로페논 화합물를 유효성분으로 포함하는 신경계 염증질환 예방 및 치료용 약학조성물 |
PL2810198T3 (pl) | 2012-01-30 | 2024-01-22 | Universiteit Gent | Związki przeciwinwazyjne |
KR101438655B1 (ko) * | 2012-04-30 | 2014-09-17 | 한국과학기술연구원 | 산화질소 생성 억제 효과와 Nrf2 활성 효과를 통해 뇌신경 질환 예방 및 치료용으로 사용 가능한 활성화된 비닐기를 포함하는 벤질 유도체 화합물 및 이의 약학조성물 |
KR101424361B1 (ko) * | 2012-07-03 | 2014-08-01 | 영남대학교 산학협력단 | 하이드록시 챨콘 화합물을 유효성분으로 함유하는 항염 조성물 |
KR101426210B1 (ko) * | 2013-09-26 | 2014-08-05 | 영남대학교 산학협력단 | 하이드록시 챨콘 화합물을 유효성분으로 함유하는 혈관신생으로 인한 질환의 예방 또는 치료용 조성물 |
CN106265612A (zh) * | 2016-10-09 | 2017-01-04 | 沈阳药科大学 | 龙血素c在制备防治中枢神经系统疾病药物中的应用 |
CN110669106B (zh) * | 2018-07-03 | 2021-08-24 | 北京和理咨询有限公司 | 一种成骨靶向肽修饰的查尔酮衍生物及其制备方法和应用 |
CN110664792B (zh) * | 2018-07-03 | 2022-08-09 | 北京和理咨询有限公司 | 一种用于脊柱融合复合的组合物及其制备方法和应用 |
KR102085868B1 (ko) * | 2018-07-23 | 2020-03-06 | 대전대학교 산학협력단 | 찰콘 유도체를 포함하는 피부 미백용 조성물 |
KR102127407B1 (ko) * | 2018-08-17 | 2020-07-07 | 한국과학기술연구원 | 신규한 할로-(3-(페닐설포닐)프로프-1-에닐)피리딘 유도체 및 이의 용도 |
CN109620819B (zh) * | 2018-12-20 | 2021-06-22 | 西安交通大学 | (1,2,3-三甲氧基苯)-丙烯酮在制备改善老年性视网膜黄斑变性药物中的应用 |
KR102231354B1 (ko) * | 2020-05-22 | 2021-03-24 | 한국과학기술연구원 | 찰콘 유도체를 포함하는 시신경 보호용 조성물 |
KR102408169B1 (ko) * | 2020-08-28 | 2022-06-14 | 주식회사 포스코 | 오카닌을 함유하는 항노화 또는 피부재생용 조성물 |
CN115400106B (zh) * | 2022-08-18 | 2024-01-19 | 清华大学 | 一种天然化合物及其组合物在清除衰老细胞方面的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999000114A2 (en) * | 1997-06-26 | 1999-01-07 | Statens Serum Institut | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones |
JP2000080035A (ja) * | 1998-09-02 | 2000-03-21 | National Institute Of Fruit Tree Science | マトリックスメタロプロテアーゼ産生阻害剤 |
US6051602A (en) * | 1998-03-16 | 2000-04-18 | The Procter & Gamble Company | Methods for regulating skin appearance |
EP0998939A1 (en) * | 1998-09-09 | 2000-05-10 | The School Of Pharmacy, University Of London | Chalcone plant extracts for use in therapy |
WO2001046110A2 (en) * | 1999-12-23 | 2001-06-28 | The University Of Georgia Research Foundation, Inc. | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU9307098A (en) * | 1997-09-08 | 1999-03-29 | Arqule, Inc. | Spiro{pyrrolidine-2,3'-oxindole} compounds and methods of use |
CN1188107C (zh) * | 1998-03-16 | 2005-02-09 | 宝洁公司 | 调节皮肤外观的组合物 |
US6444647B1 (en) * | 1999-04-19 | 2002-09-03 | The Procter & Gamble Company | Skin care compositions containing combination of skin care actives |
US6492326B1 (en) * | 1999-04-19 | 2002-12-10 | The Procter & Gamble Company | Skin care compositions containing combination of skin care actives |
US7235249B2 (en) * | 2002-03-28 | 2007-06-26 | The Procter & Gamble Company | Methods for regulating the condition of mammalian keratinous tissue via topical application of vitamin B6 compositions |
-
2001
- 2001-11-01 KR KR1020010067950A patent/KR100567125B1/ko active IP Right Grant
-
2002
- 2002-10-31 WO PCT/KR2002/002031 patent/WO2003037315A1/en not_active Application Discontinuation
- 2002-10-31 EP EP02802394.3A patent/EP1450777B1/en not_active Expired - Lifetime
- 2002-10-31 ES ES02802394T patent/ES2422891T3/es not_active Expired - Lifetime
-
2004
- 2004-05-03 US US10/838,853 patent/US7572831B2/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999000114A2 (en) * | 1997-06-26 | 1999-01-07 | Statens Serum Institut | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones |
US6051602A (en) * | 1998-03-16 | 2000-04-18 | The Procter & Gamble Company | Methods for regulating skin appearance |
JP2000080035A (ja) * | 1998-09-02 | 2000-03-21 | National Institute Of Fruit Tree Science | マトリックスメタロプロテアーゼ産生阻害剤 |
EP0998939A1 (en) * | 1998-09-09 | 2000-05-10 | The School Of Pharmacy, University Of London | Chalcone plant extracts for use in therapy |
WO2001046110A2 (en) * | 1999-12-23 | 2001-06-28 | The University Of Georgia Research Foundation, Inc. | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states |
Non-Patent Citations (2)
Title |
---|
Arthritis Research, 2001 February, 3(3), pp.147-153 * |
다양한 플라보노이드 유도체 TABLE III.생약학회지,Vol 23(4),p201-210,1992 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101220417B1 (ko) | 2010-11-04 | 2013-01-10 | 건국대학교 산학협력단 | 세포사멸 유도 활성을 갖는 칼콘 유도체 |
WO2013054998A1 (ko) * | 2011-10-13 | 2013-04-18 | 건국대학교 산학협력단 | 신규한 칼콘 유도체 및 이를 유효성분으로 하는 항암제 조성물 |
KR101389529B1 (ko) | 2012-02-03 | 2014-04-29 | 주식회사 스킨앤테크 | 가용화된 4-메톡시칼콘을 함유하는 피부 미백 조성물 및 이의 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
KR20030036993A (ko) | 2003-05-12 |
WO2003037315A1 (en) | 2003-05-08 |
EP1450777B1 (en) | 2013-05-08 |
EP1450777A1 (en) | 2004-09-01 |
US7572831B2 (en) | 2009-08-11 |
US20040209952A1 (en) | 2004-10-21 |
ES2422891T3 (es) | 2013-09-16 |
EP1450777A4 (en) | 2010-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100567125B1 (ko) | 칼콘 또는 이의 유도체를 함유하는 매트릭스메탈로프로테아제 활성 억제용 약학 조성물 | |
Cai et al. | Astilbin suppresses collagen-induced arthritis via the dysfunction of lymphocytes | |
ES2242402T3 (es) | Inhibidores de tace. | |
US10487113B2 (en) | Peptide having activity to improve skin condition and use thereof | |
JPH08104628A (ja) | マトリックスメタロプロテアーゼ阻害剤 | |
JP2013240326A (ja) | 癌および皮膚病変の処置のためのグリコシルホスファチジルイノシトール(gpi)アンカーに連結されたメタロプロテイナーゼの組織インヒビター | |
JP2002514180A (ja) | マトリックスメタロプロテイナーゼを阻害するための化合物およびその方法 | |
DE60008548T2 (de) | Hydroxamsäurederivate als matrix-metalloproteinase-inhibitoren | |
CA2356053A1 (en) | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases | |
RU2742337C2 (ru) | Циклическое соединение | |
KR100882265B1 (ko) | 칠엽수잎 추출물의 제조방법 | |
JP4521894B2 (ja) | マトリックスメタロプロテアーゼ阻害剤 | |
KR100473688B1 (ko) | 멜리사엽 엑스를 유효성분으로 하는 매트릭스메탈로프로테아제 활성 억제용 약학적 조성물 | |
KR20100060940A (ko) | Mmp-2 생성 억제용 조성물 | |
US5973110A (en) | Cytotoxic T-lymphocyte antigen as cysteine protease inhibitor | |
JPH02223525A (ja) | 血管新生阻害剤 | |
KR100450578B1 (ko) | 엔엠23 단백질을 유효성분으로 하는, 매트릭스메탈로프로테아제 활성 억제 및 혈관신생 억제용 조성물 | |
KR20200061428A (ko) | 사이클릭카복실산 유도체, 이의 제조방법 및 이를 함유하는 관절염 예방 및 치료용 약학적 조성물 | |
KR100533777B1 (ko) | 칠엽수 추출물을 유효성분으로 하는 혈관신생 억제용 조성물 | |
JP2006500422A (ja) | 酵素活性を阻害するためのキレート化剤の親油性ジエステル | |
KR100477507B1 (ko) | 은행엽 엑스를 유효성분으로하는 매트릭스메탈로프로테아제 활성 억제용 약학적 조성물 | |
KR100808131B1 (ko) | 인간 섬유육종 세포에서 메트릭스 메탈로프로테이나제-9의발현을 억제시키는 카복실화 키토올리고사카라이드 화합물및 이를 함유한 메트릭스 메탈로프로테이나제-9 억제제 | |
WO2006126747A2 (en) | Matrix metalloproteinase-9 inhibitor containing chlorogenic acid | |
US20020082200A1 (en) | Use of inhibitors of human S-CD23 | |
EP0909169A1 (en) | Medical use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B601 | Maintenance of original decision after re-examination before a trial | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20040625 Effective date: 20050929 |
|
S901 | Examination by remand of revocation | ||
E902 | Notification of reason for refusal | ||
GRNO | Decision to grant (after opposition) | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130323 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140325 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150527 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160325 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170324 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180326 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20190311 Year of fee payment: 14 |